0.6800 0.00 (0.13%)
After hours: 7:56PM EDT
|Bid||0.6750 x 2700|
|Ask||0.6799 x 500|
|Day's Range||0.6507 - 0.7460|
|52 Week Range||0.6507 - 3.4200|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.
Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastatic breast cancer.
Shares of Celldex Therapeutics Inc. plummeted 40% in premarket trade Monday toward a record low, after the drug maker said a phase 2b trial of its treatment of triple-negative breast cancer failed to meet ...
Today I will take a look at Celldex Therapeutics Inc’s (NASDAQ:CLDX) most recent earnings update (31 December 2017) and compare these latest figures against its performance over the past fewRead More...
Celldex Therapeutics Inc’s (NASDAQ:CLDX): Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. The US$331.52M market-cap company announced aRead More...
Since Celldex Therapeutics Inc (NASDAQ:CLDX) released its earnings in December 2017, analyst consensus outlook seem pessimistic, as a -27.84% fall in profits is expected in the upcoming year. Though thisRead More...
Celldex (CLDX) reports narrower-than-expected loss in Q4 with sales also beating estimates. Moreover, shares rise in after-hours trading on Mar 7 following the results.
On a per-share basis, the Hampton, New Jersey-based company said it had a loss of 3 cents. Losses, adjusted for pretax gains and non-recurring gains, were 17 cents per share. The results exceeded Wall ...
Merck's (MKGAF) Healthcare and Life Science segments are likely to drive sales in Q4. However, the company's oncology drug fails in a phase III gastric cancer study.
A small biotech, a Chinese tech giant, and the world's biggest coffee seller may be surprising choices to outgain Tesla. Keep reading to learn why they're on track to be better investments.
After a decades-long journey, 2018 could be the year Celldex Therapeutics transitions from a clinical-stage biotech to one with a product to sell.
Shopify has been a solid growth vehicle for investors, but these three stocks might be even better picks going forward.